Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

60 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Design and optimisation of orally active TLR7 agonists for the treatment of hepatitis C virus infection.
Tran TD, Pryde DC, Jones P, Adam FM, Benson N, Bish G, Calo F, Ciaramella G, Dixon R, Duckworth J, Fox DN, Hay DA, Hitchin J, Horscroft N, Howard M, Gardner I, Jones HM, Laxton C, Parkinson T, Parsons G, Proctor K, Smith MC, Smith N, Thomas A. Tran TD, et al. Among authors: laxton c. Bioorg Med Chem Lett. 2011 Apr 15;21(8):2389-93. doi: 10.1016/j.bmcl.2011.02.092. Epub 2011 Mar 16. Bioorg Med Chem Lett. 2011. PMID: 21419626
Discovery of a highly potent series of TLR7 agonists.
Jones P, Pryde DC, Tran TD, Adam FM, Bish G, Calo F, Ciaramella G, Dixon R, Duckworth J, Fox DN, Hay DA, Hitchin J, Horscroft N, Howard M, Laxton C, Parkinson T, Parsons G, Proctor K, Smith MC, Smith N, Thomas A. Jones P, et al. Among authors: laxton c. Bioorg Med Chem Lett. 2011 Oct 1;21(19):5939-43. doi: 10.1016/j.bmcl.2011.07.076. Epub 2011 Aug 4. Bioorg Med Chem Lett. 2011. PMID: 21885277
Selection, optimization, and pharmacokinetic properties of a novel, potent antiviral locked nucleic acid-based antisense oligomer targeting hepatitis C virus internal ribosome entry site.
Laxton C, Brady K, Moschos S, Turnpenny P, Rawal J, Pryde DC, Sidders B, Corbau R, Pickford C, Murray EJ. Laxton C, et al. Antimicrob Agents Chemother. 2011 Jul;55(7):3105-14. doi: 10.1128/AAC.00222-11. Epub 2011 Apr 18. Antimicrob Agents Chemother. 2011. PMID: 21502629 Free PMC article.
The innate immune response, clinical outcomes, and ex vivo HCV antiviral efficacy of a TLR7 agonist (PF-4878691).
Fidock MD, Souberbielle BE, Laxton C, Rawal J, Delpuech-Adams O, Corey TP, Colman P, Kumar V, Cheng JB, Wright K, Srinivasan S, Rana K, Craig C, Horscroft N, Perros M, Westby M, Webster R, van der Ryst E. Fidock MD, et al. Among authors: laxton c. Clin Pharmacol Ther. 2011 Jun;89(6):821-9. doi: 10.1038/clpt.2011.60. Epub 2011 Mar 30. Clin Pharmacol Ther. 2011. PMID: 21451504 Clinical Trial.
Design, synthesis, and antiviral properties of 4'-substituted ribonucleosides as inhibitors of hepatitis C virus replication: the discovery of R1479.
Smith DB, Martin JA, Klumpp K, Baker SJ, Blomgren PA, Devos R, Granycome C, Hang J, Hobbs CJ, Jiang WR, Laxton C, Le Pogam S, Leveque V, Ma H, Maile G, Merrett JH, Pichota A, Sarma K, Smith M, Swallow S, Symons J, Vesey D, Najera I, Cammack N. Smith DB, et al. Among authors: laxton c. Bioorg Med Chem Lett. 2007 May 1;17(9):2570-6. doi: 10.1016/j.bmcl.2007.02.004. Epub 2007 Feb 4. Bioorg Med Chem Lett. 2007. PMID: 17317178
The novel nucleoside analog R1479 (4'-azidocytidine) is a potent inhibitor of NS5B-dependent RNA synthesis and hepatitis C virus replication in cell culture.
Klumpp K, Lévêque V, Le Pogam S, Ma H, Jiang WR, Kang H, Granycome C, Singer M, Laxton C, Hang JQ, Sarma K, Smith DB, Heindl D, Hobbs CJ, Merrett JH, Symons J, Cammack N, Martin JA, Devos R, Nájera I. Klumpp K, et al. Among authors: laxton c. J Biol Chem. 2006 Feb 17;281(7):3793-9. doi: 10.1074/jbc.M510195200. Epub 2005 Nov 29. J Biol Chem. 2006. PMID: 16316989 Free article.
60 results